Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.43 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.40 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.40 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.40 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5296044 | 0.98 | TLR8 (0.59) | TLR8ALDH1A1POLBKMT2AKCNH2 | |
| SCHEMBL11015818 | 0.98 | TLR8 (0.59) | TLR8ALDH1A1POLBKMT2AKCNH2 | |
| SCHEMBL9186379 | 0.98 | TLR8 (0.59) | TLR8ALDH1A1POLBKMT2AKCNH2 | |
| SCHEMBL5303316 | 0.98 | TLR8 (0.59) | TLR8ALDH1A1POLBKMT2AKCNH2 | |
| SCHEMBL2149023 | 0.98 | TLR8 (0.59) | TLR8ALDH1A1POLBKMT2AKCNH2 | |
| SCHEMBL5283349 | 0.98 | TLR8 (0.59) | TLR8ALDH1A1POLBKMT2AKCNH2 | |
| SCHEMBL5282914 | 0.98 | TLR8 (0.59) | TLR8ALDH1A1POLBKMT2AKCNH2 | |
| SCHEMBL902477 | 0.98 | TLR8 (0.59) | TLR8ALDH1A1POLBKMT2AKCNH2 | |
| SCHEMBL5286463 | 0.98 | TLR8 (0.59) | TLR8ALDH1A1POLBKMT2AKCNH2 | |
| SCHEMBL4071947 | 0.98 | TLR8 (0.59) | TLR8ALDH1A1POLBKMT2AKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 284 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114957128-B | Diaryl imidazolium salt and antibacterial application thereof | 四川大学 | 2024-07-23 | — | — | CN | claimed |
| CN-114957128-A | Diaryl imidazolium salt and antibacterial application thereof | 四川大学 | 2022-08-30 | — | — | CN | claimed |
| CN-109320458-B | Diaryl imidazole-containing compound, preparation method and medical application thereof | 中国药科大学 | 2022-05-31 | — | — | CN | claimed |
| CN-110791547-A | Creatinine quantitative detection dry sheet for in vitro diagnosis | 无锡锦帛诚医疗器械科技有限公司 | 2020-02-14 | — | — | CN | claimed |
| CN-109320458-A | One kind is containing diarylimidazoles and preparation method thereof and medical usage | 中国药科大学 | 2019-02-12 | — | — | CN | claimed |
| US-9834723-B2 | Pentaarylbiimidazole compound and production method for said compound | KANTO KAGAKU KABUSHIKI KAISHA (JP) | 2017-12-05 | — | — | US | claimed |
| US-20170130124-A1 | PENTAARYLBIIMIDAZOLE COMPOUND AND PRODUCTION METHOD FOR SAID COMPOUND | KANTO KAGAKU KABUSHIKI KAISHA (JP) | 2017-05-11 | — | — | US | claimed |
| EP-1752149-A1 | CB1 Antagonists or inverse agonists as therapeutical agents for the treatment of inflammation involving gene expression | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-02-14 | — | — | EP | claimed |
| US-6515133-B1 | Certain diaryl imidazoles act as partial agonists or antagonists for NPY receptors, in particular NPY 5 receptors. They are of use, for example in treating loss of appetite. Such compounds bear aryl groups in the 2 position. | NEUROGEN CORPORATION | 2003-02-04 | — | — | US | claimed |
| EP-0996443-A1 | CERTAIN DIARYLIMIDAZOLE DERIVATIVES; A NEW CLASS OF NPY SPECIFIC LIGANDS | NEUROGEN CORPORATION (US) | 2000-05-03 | — | — | EP | claimed |
| EP-0620283-B1 | Method for colourimetric determination of an analyte by using a PQQ-dependent dehydrogenase | BOEHRINGER MANNHEIM GMBH (DE) | 1998-09-16 | — | — | EP | claimed |
| US-5506116-A | MIXING WITH NADH, TYROSINASE AND DYE, COLORIMETRIC ANALYSIS | JOHNSON & JOHNSON CLINICAL DIAGNOSTICS, INC. (US) | 1996-04-09 | — | — | US | claimed |
| US-5484708-A | DETERMINATION OF GLUCOSE | BOEHRINGER MANNHEIM GMBH (DE) | 1996-01-16 | — | — | US | claimed |
| EP-0620283-A1 | Method for colourimetric determination of an analyte by using a PQQ-dependent dehydrogenase | Roche Diagnostics GmbH (DE) | 1994-10-19 | — | — | EP | claimed |
| EP-0402667-B1 | Diarylimidazoles | BOEHRINGER MANNHEIM GMBH (DE) | 1994-02-02 | — | — | EP | claimed |
| US-5274095-A | A 4-(4-(julolid-9-yl)imidazol-2-yl-2,6-ditert-butyl-phenol derivative | BOEHRINGER MANNHEIM GMBH (DE) | 1993-12-28 | — | — | US | claimed |
| US-5162200-A | METHOD FOR DETERMINATION OF A PEROXIDATE-ACTING SUBSTANCE WITH A DIARYLIMIDAZOLE COMPOUND | BOEHRINGER MANNEHEIM GMBH (DE) | 1992-11-10 | — | — | US | claimed |
| EP-0398941-A4 | DRY POWDER DIAGNOSTIC REAGENT AND APPLICATIONS THEREOF | — | 1991-04-10 | — | — | EP | claimed |
| EP-0398941-A1 | DRY POWDER DIAGNOSTIC REAGENT AND APPLICATIONS THEREOF | BOEHRINGER MANNHEIM CORPORATION (US) | 1990-11-28 | — | — | EP | claimed |
| WO-1989006284-A1 | DRY POWDER DIAGNOSTIC REAGENT AND APPLICATIONS THEREOF | BOEHRINGER MANNHEIM CORPORATION (US) | 1989-07-13 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170130124-A1 | PENTAARYLBIIMIDAZOLE COMPOUND AND PRODUCTION METHOD FOR SAID COMPOUND | PPOX, CDK4, PAICS | TLR8 2888/4885ALDH1A1 432/4885POLB 641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.